In addition, the high drug-to-antibody ratio of T-DXd can deliver higher payload concentrations to cancer cells, giving it more potent antitumor activity than other ADCs.[10] T-DM1 therapy is an option for patients with metastatic HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.